KR101378353B1 - 세포 사이클의 비정기 활성과 연관된 질환 또는 신경퇴행성 장애를 치료하는 데에 유용한 ｃｄｋ４／ｃｄｋ６ 억제제를 부호화하는 유도 유전자를 포함하는 벡터 - Google Patents

세포 사이클의 비정기 활성과 연관된 질환 또는 신경퇴행성 장애를 치료하는 데에 유용한 ｃｄｋ４／ｃｄｋ６ 억제제를 부호화하는 유도 유전자를 포함하는 벡터 Download PDF

Info

Publication number
KR101378353B1
KR101378353B1 KR1020117020766A KR20117020766A KR101378353B1 KR 101378353 B1 KR101378353 B1 KR 101378353B1 KR 1020117020766 A KR1020117020766 A KR 1020117020766A KR 20117020766 A KR20117020766 A KR 20117020766A KR 101378353 B1 KR101378353 B1 KR 101378353B1
Authority
KR
South Korea
Prior art keywords
vector
promoter
expression
cdk4
ink4a
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020117020766A
Other languages
English (en)
Korean (ko)
Other versions
KR20110121704A (ko
Inventor
토마스 아덴트
우베 위버람
Original Assignee
우니베르지태트 라이치히
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 우니베르지태트 라이치히 filed Critical 우니베르지태트 라이치히
Publication of KR20110121704A publication Critical patent/KR20110121704A/ko
Application granted granted Critical
Publication of KR101378353B1 publication Critical patent/KR101378353B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020117020766A 2009-02-04 2010-02-04 세포 사이클의 비정기 활성과 연관된 질환 또는 신경퇴행성 장애를 치료하는 데에 유용한 ｃｄｋ４／ｃｄｋ６ 억제제를 부호화하는 유도 유전자를 포함하는 벡터 Expired - Fee Related KR101378353B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09001521A EP2218784A1 (en) 2009-02-04 2009-02-04 Vector(s) containing an inducible gene encoding a CDK4/CD6 inhibitor useful for treating neurodegenerative disorders
EP09001521.5 2009-02-04
PCT/EP2010/000702 WO2010089122A2 (en) 2009-02-04 2010-02-04 Vector(s) containing an inducible gene encoding a cdk4/cdk6 inhibitor useful for treating neurodegenerative disorders or diseases associated with an unscheduled activation of the cell cycle

Publications (2)

Publication Number Publication Date
KR20110121704A KR20110121704A (ko) 2011-11-08
KR101378353B1 true KR101378353B1 (ko) 2014-04-10

Family

ID=40673417

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117020766A Expired - Fee Related KR101378353B1 (ko) 2009-02-04 2010-02-04 세포 사이클의 비정기 활성과 연관된 질환 또는 신경퇴행성 장애를 치료하는 데에 유용한 ｃｄｋ４／ｃｄｋ６ 억제제를 부호화하는 유도 유전자를 포함하는 벡터

Country Status (8)

Country Link
US (2) US20120004277A1 (https=)
EP (2) EP2620447B1 (https=)
JP (1) JP5869884B2 (https=)
KR (1) KR101378353B1 (https=)
CN (1) CN102356156A (https=)
AU (1) AU2010211289B2 (https=)
CA (1) CA2751531A1 (https=)
WO (1) WO2010089122A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8653324B2 (en) * 2010-06-11 2014-02-18 Fox Chase Cancer Center TetO-p16 transgenic mice
WO2012050975A2 (en) * 2010-09-29 2012-04-19 The University Of North Carolina At Chapel Hill Novel circular mammalian rna molecules and uses thereof
KR101255338B1 (ko) * 2010-12-15 2013-04-16 포항공과대학교 산학협력단 표적 세포에 대한 폴리뉴클레오티드 전달체
KR20140041505A (ko) 2011-04-29 2014-04-04 셀렉타 바이오사이언시즈, 인크. 조절 b 세포 유도를 위한 관용원성 합성 나노운반체
HUE052599T2 (hu) 2013-05-03 2021-05-28 Selecta Biosciences Inc CD4+ szabályozó T-sejtek fokozására szolgáló eljárások és készítmények
AU2015311704B2 (en) * 2014-09-07 2021-12-09 Selecta Biosciences, Inc. Methods and compositions for attenuating gene editing anti-viral transfer vector immune responses
US20180230489A1 (en) 2015-10-28 2018-08-16 Voyager Therapeutics, Inc. Regulatable expression using adeno-associated virus (aav)
WO2018169811A1 (en) 2017-03-11 2018-09-20 Selecta Biosciences, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
CN108319816B (zh) * 2018-02-27 2021-04-23 广州大学 一种基于基因通路识别小分子核糖核酸的方法
CN114207440A (zh) 2019-06-04 2022-03-18 西莱克塔生物科技公司 聚乙二醇化尿酸酶的制剂和剂量

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19936034C1 (de) * 1999-07-30 2001-01-25 Univ Leipzig Rekombiniertes, neuronalspezifisch aktiviertes, transkribierbares lineares DNA-Konstrukt
WO2005033277A2 (en) * 2003-09-29 2005-04-14 University Of Rochester Methods of modulating cell cycle and cell signaling pathways using biliverdin reductase
JP4956427B2 (ja) * 2004-07-21 2012-06-20 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド レンチウイルスベクターおよびその使用
EP1838841A2 (en) * 2004-12-23 2007-10-03 The Ludwig Institute for Cancer Research Engineered dopamine neurons and uses thereof
US20080300202A1 (en) * 2006-05-18 2008-12-04 The State of Oregon acting by and through the State Board of Higher Education on behalf of the Subtractive transgenics
US9394538B2 (en) * 2008-05-07 2016-07-19 Shi-Lung Lin Development of universal cancer drugs and vaccines

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DAVID GOUKASSIAN 등. The FASEB Journal. 2001, Vol. 15, No. 11. 페이지 1877-1885. *
DAVID GOUKASSIAN 등. The FASEB Journal. 2001, Vol. 15, No. 11. 페이지 1877-1885.*
XI CHEN 등. Cell Research. 2002, Vol. 12, No. 3-4. 페이지 229-233. *
XI CHEN 등. Cell Research. 2002, Vol. 12, No. 3-4. 페이지 229-233.*

Also Published As

Publication number Publication date
WO2010089122A2 (en) 2010-08-12
CN102356156A (zh) 2012-02-15
EP2620447B1 (en) 2015-09-09
WO2010089122A3 (en) 2010-12-09
JP5869884B2 (ja) 2016-02-24
AU2010211289A1 (en) 2011-09-01
US20120004277A1 (en) 2012-01-05
KR20110121704A (ko) 2011-11-08
EP2620447A1 (en) 2013-07-31
JP2012516691A (ja) 2012-07-26
US20160144054A1 (en) 2016-05-26
CA2751531A1 (en) 2010-08-12
AU2010211289B2 (en) 2016-12-15
EP2218784A1 (en) 2010-08-18

Similar Documents

Publication Publication Date Title
KR101378353B1 (ko) 세포 사이클의 비정기 활성과 연관된 질환 또는 신경퇴행성 장애를 치료하는 데에 유용한 ｃｄｋ４／ｃｄｋ６ 억제제를 부호화하는 유도 유전자를 포함하는 벡터
US8389487B2 (en) siRNA-mediated gene silencing of synuclein
TWI787163B (zh) 用於減少tau表現之組合物及方法
Kim et al. Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor pathway genes: therapeutic strategy for herpetic stromal keratitis
CA2125974C (en) Senescent cell derived inhibitors of dna synthesis
US8067572B2 (en) Hybrid interfering RNA
Durbeej et al. Differential expression of neurotrophin receptors during renal development
JPH08510130A (ja) 異常スプライシングを阻害するアンチセンスオリゴヌクレオチドと同物質の利用法
AU6430599A (en) Enzymatic synthesis of ssdna
CA2771228A1 (en) Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip
Almutiri et al. Non-viral-mediated suppression of AMIGO3 promotes disinhibited NT3-mediated regeneration of spinal cord dorsal column axons
CN107365785A (zh) 一种调控细胞内NF‑κB活性的基因表达载体及其调控方法和应用
KR20230050336A (ko) 뇌전증을 치료하기 위한 방법과 조성물
Smith et al. Functional involvement of Pax‐1 in somite development: Somite dysmorphogenesis in chick embryos treated with Pax‐1 paired‐box antisense oligodeoxynucleotide
EP1534832A2 (en) Compositions and methods for tissue specific or inducible inhibition of gene expression
US20080287381A1 (en) Injectable Agent for the Targeted Treatment of Retinal Ganglion Cells
Oh et al. Fluorescence imaging of huntingtin mRNA knockdown
Wang et al. Lentivector-mediated RNAi efficiently downregulates expression of murine TNF-α gene in vitro and in vivo
JP2018515110A (ja) 多発性硬化症の治療
Huang SUPPRESSION OF KERATOEPITHELIN AND MYOCILIN BY SMALL INTERFERING RNA (AN AMERICAN OPTHALMOLOGICAL SOCIETY THESIS)
Mastroyiannopoulos et al. Myotonic Dystrophy Type 1: Focus on the RNA Pathology and Therapy
Yan Analysis and recombinant AAV delivery of ribozymes against the rd mutation in mice
Hung Combined gene therapy of siRNA and apoptosis inducing factor generated from a single transcriptional event

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20170321

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20180321

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20190304

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20200321

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20200321